Protecting Axons
Protecting Patients

Creating breakthrough therapeutics for neurological diseases

Disarm is conducting a chemotherapy-induced peripheral neuropathy (CIPN) natural history study (EPIPHANY). This prospective observational study is being conducted across multiple sites in the U.S. and will characterize CIPN disease course and associated biomarkers.

Learn More +

Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer

January 13, 2020

press release

+

Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo

October 22, 2019

press release

+

A New Approach to Treating Multiple Sclerosis

News

+